Study of Blood Platelets in Sickle Cell Disease

This study has been withdrawn prior to enrollment.
(PI returned to India)
Sponsor:
Collaborators:
Icahn School of Medicine at Mount Sinai
Schneider Children's Hospital of North Shore
Information provided by (Responsible Party):
Rockefeller University
ClinicalTrials.gov Identifier:
NCT00226083
First received: September 22, 2005
Last updated: June 5, 2015
Last verified: June 2015
  Purpose

We are studying if sickle cell disease blood platelets are larger than normal and how they may cause obstruction of blood vessels. We are also trying to study the reasons why large platelets are found in patients with sickle cell disease.


Condition
Sickle Cell Disease

Study Type: Observational
Study Design: Time Perspective: Prospective
Official Title: Studies of Large Platelets in Patients With Sickle Cell Disease

Resource links provided by NLM:


Further study details as provided by Rockefeller University:

Enrollment: 0
Study Start Date: August 2005
Estimated Study Completion Date: September 2007
Estimated Primary Completion Date: September 2007 (Final data collection date for primary outcome measure)
Detailed Description:

Research volunteers are seen in the Outpatient Research Center by the Principal Investigator or another physician. A detailed history is obtained, a physical examination is performed, and blood (usually 4 tablespoons) is obtained for additional tests. The research volunteer's previous medical records will be requested. Upto 5 additional blood samples may be obtained in a subgroup of patients.

  Eligibility

Ages Eligible for Study:   7 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Sampling Method:   Non-Probability Sample
Study Population

Adults and children with sickle cell disease (Hb SS)

Criteria

Inclusion Criteria:

  • Adults and children > 7 years of age with sickle cell disease (Hb SS) who are not taking hydroxyurea and are not receiving routine blood transfusion therapy.

Exclusion Criteria:

  • Current hydroxyurea therapy or,
  • Hydroxyurea use within the past 3 months
  • Blood transfusion or exchange transfusion within the past 3 months
  • Current treatment with aspirin or clopidogrel
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00226083

Locations
United States, New York
Rockefeller University Hospital
New York, New York, United States, 10021
Sponsors and Collaborators
Rockefeller University
Icahn School of Medicine at Mount Sinai
Schneider Children's Hospital of North Shore
Investigators
Principal Investigator: Arun Shet, MD Rockefeller University
  More Information

No publications provided

Responsible Party: Rockefeller University
ClinicalTrials.gov Identifier: NCT00226083     History of Changes
Other Study ID Numbers: RUH IRB # AST-0565-0805
Study First Received: September 22, 2005
Last Updated: June 5, 2015
Health Authority: United States: Food and Drug Administration

Additional relevant MeSH terms:
Anemia, Sickle Cell
Anemia
Anemia, Hemolytic
Anemia, Hemolytic, Congenital
Genetic Diseases, Inborn
Hematologic Diseases
Hemoglobinopathies

ClinicalTrials.gov processed this record on July 01, 2015